Macular Amyloidosis. Amyloidosis of skin, Lichen amyloidosis, Macular amyloid
Conditions
Interventions
Intervention 1: In this side, intralesional injection of tranexamic acid (Tranexamic acid, concentration: 500 mg in 5 mL
brand name: Tranexip, manufactured by Caspian Pharmaceutical Company) is administered. The injection is performed intradermally using a 1 mL insulin syringe and, at an approximate depth of 1 cm. A vol
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients must be 18 years of age or older. Patients must have a diagnosis of cutaneous amyloidosis via clinical manifestations. Patients must be willing to provide informed consent.
Exclusion criteria
Exclusion criteria: Patients have a history of sensitivity to TXA or PRP components. Patients are currently using anticoagulants or antiplatelet therapy. Patients have an active infection at the injection site. Patients are pregnant or breastfeeding. Patients have a history of treatment with anti-pigmentation drugs in the past 3 months. Patients have a history of recent bleeding for any reason. Patients are undergoing hormone therapy or concomitant use of contraceptives. Patients have used topical treatments containing corticosteroids, peels, or lighteners in the study areas within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient scoring of changes in color and itching of skin lesions. Timepoint: Treatment response is assessed at 4, 8, and 12 weeks after initiation, as well as 3 months after the end of treatment, and compared to baseline (day zero). Method of measurement: The researcher-designed questionnaire included a 5-point ordinal scale to assess the degree of improvement, satisfaction with the appearance of the lesions, and reduction of symptoms such as itching and pain from the patient's perspective; scoring was done as follows: 0 = no improvement, 1 = slight improvement (75%).;Scoring of changes in skin lesion color by two dermatologists. Timepoint: Treatment response is assessed at 4, 8, and 12 weeks after initiation, as well as 3 months after the end of treatment, and compared to baseline (day zero). Method of measurement: Patients are examined by two dermatologists and the degree of improvement of their lesions is scored: 0 no improvement, 1 slight improvement (75%).;Scoring of changes in dermoscopic criteria and evaluation of patterns in macular amyloidosis. Timepoint: Treatment response is assessed at 4, 8, and 12 weeks after initiation, as well as 3 months after the end of treatment, and compared to baseline (day zero). Method of measurement: Dermoscopic criteria will be evaluated by two board-certified dermatologists during physical examinations using a dermoscope. The evaluation will be based on predefined dermoscopic parameters such as pigmentation pattern, presence of rippling, central hub, and perifollicular changes. Assessments will be performed before and after the intervention. Each criterion will be scored as improved, unchanged, or worsened. In case of disagreement between the two dermatologists, consensus will be reached or the mean score will be used. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKiana Rahmati
Mashhad University of Medical Sciences
Outcome results
None listed